Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 13Pheochromocytoma 6Carcinoma, Neuroendocrine 6Somatostatinoma 5Paraganglioma 4Pituitary Neoplasms 3Insulinoma 3Glucagonoma 3Gastrinoma 3Zollinger-Ellison Syndrome 2Vipoma 2Paraganglioma, Extra-Adrenal 2Pancreatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoma, Islet Cell 2Carcinoid Tumor 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Prolactinoma 1Optic Nerve Glioma 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1

Interventions

lanreotide 1antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Surveys and Questionnaires 1Solutions 1Radiosurgery 1Observation 1Microarray Analysis 1Injections 1Early Intervention, Educational 1Diet, Mediterranean 1Diet, Ketogenic 1DNA Methylation 1Complementary Therapies 1Biological Therapy 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Growth Hormone-Secreting Pituitary Adenoma × Temozolomide × Endocrine × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡